Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Aberrant Crypt Foci
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
14507667 |
2003 |
Abnormal dermatoglyphic pattern
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormal form of the vertebral bodies
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal pigmentation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of canine
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of dental enamel
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Abnormality of retinal pigmentation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of the abdominal wall
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of the metacarpal bones
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of the musculature
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of the ribs
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abscess cavity
|
0.010 |
Biomarker
|
disease |
BEFREE |
After completion of APC and VAC therapy, the patient irrigated the abscess cavity for a further 2 weeks with a rinsing syringe.
|
31435733 |
2019 |
Absent fingernail
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Absent toenail
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Acinar Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway.
|
11891193 |
2002 |
Acinar cell carcinoma of pancreas
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation.
|
24590585 |
2014 |
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that homozygous FV-deficient plasma completely lacks the cofactor, i.e. the second APC cofactor, which can correct APC resistance in plasma.
|
7865690 |
1994 |
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Factor VThr306 is the first description of a mutation affecting the Arg306 APC cleavage site and is the only mutation, other than factor V Leiden (Arg506-->Gln), that has been found in association with APC resistance.
|
9454742 |
1998 |
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
APC-R was on an automated hemostasis analyzer, and values less than 2.0 were reported as APC-R. Polymerase chain reaction and restricted fragment length polymorphism tests were performed using standard methods, and the results were reported as normal wild-type homozygous GG, FVL homozygous AA, or FVL heterozygous GA.
|
20736749 |
2010 |
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
|
16934314 |
2007 |
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In individuals with normal factor V genotype, the original APC-resistance test gave significantly lower APC-ratio values both in DVT-positive and DVT-negative patients than in healthy controls.
|
9157592 |
1997 |
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study we found no difference between the prevalence of APC resistance (assessed by the ratio of the aPTT with and without added APC) in 134 non-anticoagulated survivors of myocardial infarction and that in 100 controls of similar age and sex distribution (2.2% and 2.0%, respectively).
|
8589213 |
1995 |
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Its allelic frequencies were found to differ significantly (P=0.003) between subjects selected for increased APCR in the absence of the FV R506Q mutation (n=70, normalized ratios </=0.80), and for increased APC sensitivity (n=98, normalized ratios >/=1.31).
|
12783110 |
2003 |
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
A reduced response to APC (APC-resistance) was found in 49% of 65 PLa-positive and in 13% of 90 PLa-negative samples (chi 2 = 23.9; p < 0.5 x 10(-4)).
|
7631299 |
1995 |